(Total Views: 684)
Posted On: 10/26/2020 9:51:39 AM
Post# of 148892
You can both be right, you know.
Ohm, I agree with you that so much is known about CCR5 that there likely is merit to the stroke indication and, on a long enough timeline, leronlimab may be an approved drug for stroke victims generating revenue for its owner. As an aside, thanks for your fantastic input on the science side of this investment. Invaluable.
However, it's also reasonable to be frustrated by the scattershot approach of CYDY management and the continued clear pumping press releases.
Correlation is not causation, but this morning's entire PR was premised on the correlation between administering leronlimab to two (2!!!) stroke victims followed by apparent, qualitative improvement. No data - just more anecdotes. As a result, it's extremely hard for the average investor, who has not researched the science extensively as you have, to take CYDY seriously.
Like I said, you're both right. It's a matter of timeline and probabilities of success for CYDY. LL may end up having a role in many indications. It may end up the best selling drug of all time, who knows.
Despite the strong science, some long-time shareholders, myself included, have started to seriously doubt CYDY's ability to get any indication over the goal line. The constant delays cost money and time, and CYDY perpetually has none of the former and precious little of the latter (there is ALWAYS competition).
SOMEONE ultimately will make money off of leronlimab. The science is too strong. Whether those someones are CYDY and its shareholders is an entirely separate question.
Speaking of money, I am going to go out on a limb and predict that the Friday proactive video, followed by this morning's PR, are clear signals that CYDY is in the process of raising money right now.
Nothing to back that up other than being in the stock the last 3.5 years and watching the pattern repeat.
Good luck to you both!
BL.
Ohm, I agree with you that so much is known about CCR5 that there likely is merit to the stroke indication and, on a long enough timeline, leronlimab may be an approved drug for stroke victims generating revenue for its owner. As an aside, thanks for your fantastic input on the science side of this investment. Invaluable.
However, it's also reasonable to be frustrated by the scattershot approach of CYDY management and the continued clear pumping press releases.
Correlation is not causation, but this morning's entire PR was premised on the correlation between administering leronlimab to two (2!!!) stroke victims followed by apparent, qualitative improvement. No data - just more anecdotes. As a result, it's extremely hard for the average investor, who has not researched the science extensively as you have, to take CYDY seriously.
Like I said, you're both right. It's a matter of timeline and probabilities of success for CYDY. LL may end up having a role in many indications. It may end up the best selling drug of all time, who knows.
Despite the strong science, some long-time shareholders, myself included, have started to seriously doubt CYDY's ability to get any indication over the goal line. The constant delays cost money and time, and CYDY perpetually has none of the former and precious little of the latter (there is ALWAYS competition).
SOMEONE ultimately will make money off of leronlimab. The science is too strong. Whether those someones are CYDY and its shareholders is an entirely separate question.
Speaking of money, I am going to go out on a limb and predict that the Friday proactive video, followed by this morning's PR, are clear signals that CYDY is in the process of raising money right now.
Nothing to back that up other than being in the stock the last 3.5 years and watching the pattern repeat.
Good luck to you both!
BL.
(10)
(0)Scroll down for more posts ▼
